Cargando…
Multi-omics approach to precision medicine for immune-mediated diseases
Recent innovation in high-throughput sequencing technologies has drastically empowered the scientific research. Consequently, now, it is possible to capture comprehensive profiles of samples at multiple levels including genome, epigenome, and transcriptome at a time. Applying these kinds of rich inf...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325815/ https://www.ncbi.nlm.nih.gov/pubmed/34332645 http://dx.doi.org/10.1186/s41232-021-00173-8 |
_version_ | 1783731625801023488 |
---|---|
author | Ota, Mineto Fujio, Keishi |
author_facet | Ota, Mineto Fujio, Keishi |
author_sort | Ota, Mineto |
collection | PubMed |
description | Recent innovation in high-throughput sequencing technologies has drastically empowered the scientific research. Consequently, now, it is possible to capture comprehensive profiles of samples at multiple levels including genome, epigenome, and transcriptome at a time. Applying these kinds of rich information to clinical settings is of great social significance. For some traits such as cardiovascular diseases, attempts to apply omics datasets in clinical practice for the prediction of the disease risk have already shown promising results, although still under way for immune-mediated diseases. Multiple studies have tried to predict treatment response in immune-mediated diseases using genomic, transcriptomic, or clinical information, showing various possible indicators. For better prediction of treatment response or disease outcome in immune-mediated diseases, combining multi-layer information together may increase the power. In addition, in order to efficiently pick up meaningful information from the massive data, high-quality annotation of genomic functions is also crucial. In this review, we discuss the achievement so far and the future direction of multi-omics approach to immune-mediated diseases. |
format | Online Article Text |
id | pubmed-8325815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83258152021-08-02 Multi-omics approach to precision medicine for immune-mediated diseases Ota, Mineto Fujio, Keishi Inflamm Regen Review Recent innovation in high-throughput sequencing technologies has drastically empowered the scientific research. Consequently, now, it is possible to capture comprehensive profiles of samples at multiple levels including genome, epigenome, and transcriptome at a time. Applying these kinds of rich information to clinical settings is of great social significance. For some traits such as cardiovascular diseases, attempts to apply omics datasets in clinical practice for the prediction of the disease risk have already shown promising results, although still under way for immune-mediated diseases. Multiple studies have tried to predict treatment response in immune-mediated diseases using genomic, transcriptomic, or clinical information, showing various possible indicators. For better prediction of treatment response or disease outcome in immune-mediated diseases, combining multi-layer information together may increase the power. In addition, in order to efficiently pick up meaningful information from the massive data, high-quality annotation of genomic functions is also crucial. In this review, we discuss the achievement so far and the future direction of multi-omics approach to immune-mediated diseases. BioMed Central 2021-08-01 /pmc/articles/PMC8325815/ /pubmed/34332645 http://dx.doi.org/10.1186/s41232-021-00173-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Ota, Mineto Fujio, Keishi Multi-omics approach to precision medicine for immune-mediated diseases |
title | Multi-omics approach to precision medicine for immune-mediated diseases |
title_full | Multi-omics approach to precision medicine for immune-mediated diseases |
title_fullStr | Multi-omics approach to precision medicine for immune-mediated diseases |
title_full_unstemmed | Multi-omics approach to precision medicine for immune-mediated diseases |
title_short | Multi-omics approach to precision medicine for immune-mediated diseases |
title_sort | multi-omics approach to precision medicine for immune-mediated diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325815/ https://www.ncbi.nlm.nih.gov/pubmed/34332645 http://dx.doi.org/10.1186/s41232-021-00173-8 |
work_keys_str_mv | AT otamineto multiomicsapproachtoprecisionmedicineforimmunemediateddiseases AT fujiokeishi multiomicsapproachtoprecisionmedicineforimmunemediateddiseases |